CREBBP bromodomain-histone interactions inhibitors (Pfizer/University of Oxford)

N/A

Report date: 2025/01/26 16:28:31
NME

Base Information

Drug NameCREBBP bromodomain-histone interactions inhibitors (Pfizer/University of Oxford)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 degraderscAMP-response element binding protein inhibitors
TargetscAMP-response element binding proteinBromodomain-containing protein 4
Therapy Area/IndicationsMetabolic DiseasesRubinstein-Taybi SyndromeNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncUniversity Of Oxford
Inactive CompaniesN/A
Active IndicationsMetabolic DiseasesRubinstein-Taybi SyndromeNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A